Abstract
We have retrospectively evaluated a cohort of 144 patients (including 17 pediatric ones) with de novo acute promyelocytic leukemia registered in databases of institutions cooperating within the CELL group. The patients where diagnosed according to WHO criteria from 1989 until 2006.
The aim was to check how well fared the patients, the majority of whom was not included into clinical trials, in real life. Our study points to a significant difference of the results obtained in real life and of the results that could be achieved in patients who were fit to enter clinical trials.
Among the prognostic factors, the most important one was the WBC count, the PS, and the feasibility of administration of the most potent induction therapy with anthracyclines and ATRA.